Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Cattle LGALS9 Protein, His-tagged

Cat.No. : LGALS9-431C
Product Overview : Recombinant Cattle LGALS9(Phe17~Gln148) fused with His tag at N-terminal was expressed in E. coli.
  • Specification
  • Gene Information
  • Related Products
Description : LGALS9 played an important role in many functions.
Source : E. coli
Species : Cattle
Tag : His
Form : PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
Molecular Mass : 16.3kDa
Identity : Reconstitute in PBS or others
Protein length : Phe17~Gln148
Endotoxin : <1.0EU per 1µg (determined by the LAL method)
Purity : > 95%
Applications : Positive Control; Immunogen; SDS-PAGE; WB.
If bio-activity of the protein is needed, please check active protein
Stability : The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
Storage : Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months.
Reconstitution : Reconstitute in PBS or others
Gene Name : LGALS9 galectin 9 [ Bos taurus ]
Official Symbol : LGALS9
Synonyms : gal-9; lectin, galactoside-binding, soluble, 9 (galectin 9)
Gene ID : 510813
mRNA Refseq : NM_001015570
Protein Refseq : NP_001015570

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
Are there any ongoing clinical trials involving LGALS9 protein? 04/12/2023

Yes, there are clinical trials investigating the use of LGALS9-based therapies in cancer treatment, with a focus on immunotherapy approaches.

Is LGALS9 protein being explored for the treatment of infectious diseases? 07/05/2022

There is emerging research on the potential use of LGALS9 in modulating immune responses to infectious diseases, particularly in the context of viral infections.

What are the potential challenges associated with the clinical application of LGALS9 protein? 03/28/2021

Challenges include optimizing the delivery and dosing of LGALS9-based therapies and addressing potential adverse effects on immune homeostasis.

How is LGALS9 protein being studied in the context of transplant immunology? 01/08/2020

LGALS9 is being investigated for its potential to induce immune tolerance and mitigate transplant rejection in preclinical studies.

How does LGALS9 protein contribute to cancer immunotherapy? 12/31/2019

LGALS9 has been found to promote the activation and proliferation of cytotoxic T lymphocytes, which are key players in the immune response against cancer cells.

Customer Reviews (3)

Write a review
Reviews
08/04/2019

    It has demonstrated outstanding performance in ELISA, providing reliable and precise results.

    05/05/2019

      It has been invaluable in protein electron microscopy structure analysis, facilitating detailed investigations and yielding valuable insights.

      03/09/2016

        I highly recommend the LGALS9 protein for various experimental applications.

        Ask a Question for All LGALS9 Products

        Required fields are marked with *

        My Review for All LGALS9 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends